专题论文

全球抗肿瘤药物研发报告(2016)

  • 毛艳艳 ,
  • 高柳滨
展开
  • 中国科学院上海药物研究所, 上海 201203
毛艳艳,馆员,研究方向为药物情报分析,电子信箱:myy@simm.ac.cn

收稿日期: 2016-05-17

  修回日期: 2016-05-29

  网络出版日期: 2016-06-29

Report on global development of antitumor drugs (2016)

  • MAO Yanyan ,
  • GAO Liubin
Expand
  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Received date: 2016-05-17

  Revised date: 2016-05-29

  Online published: 2016-06-29

摘要

癌症治疗是世界难题。抗肿瘤药物作为癌症治疗的重要方法之一,近年来呈现快速发展趋势,每年都有各类机构针对不同适应症、不同靶点进行大量的抗肿瘤药物开发。通过调研文献和数据库,综述了近10年来全球抗肿瘤药物的数量、研发阶段、适应证、作用机制、研发机构和销售等情况。

本文引用格式

毛艳艳 , 高柳滨 . 全球抗肿瘤药物研发报告(2016)[J]. 科技导报, 2016 , 34(11) : 21 -24 . DOI: 10.3981/j.issn.1000-7857.2016.11.002

Abstract

The treatment of cancer patients is a world-wide problem. Antitumor drugs, as one of the most important treatments for cancer patients, see a rapid growth in recent years with various institutions working in different indications and targets each year. Based on literature research and database retrieval, the global antitumor drug number, the development stages, the indications and the mechanisms, as well as research institutions and sales, are reviewed in this paper, focusing on the general trend and direction of the antitumor drug development.

参考文献

[1] Torre L A, Bray F, Siegel R L, et al.Global cancer statistics[J].CA: A Cancer Journal for Clinicians, 2015, 65(2): 87-108.
[2] Chen W, Zheng R, Baade P D, et al.Cancer statistics in China[J].CA: A Cancer Journal for Clinicians, 2016, 66(2): 115-132.
[3] Wu P, Nielsen T E, and Clausen M H.FDA-approved small-molecule kinase inhibitors[J].Trends in Pharmacological Sciences, 2015, 36(7): 422-39.
[4] Huang M, Shen A, Ding J, et al.Molecularly targeted cancer therapy: some lessons from the past decade[J].Trends in Pharmacological Scienc-es, 2014, 35(1): 41-50.
[5] Chen D S, Mellman I.Oncology meets immunology: The cancer-immu-nity cycle[J].Immunity, 2013, 39(1): 1-10.
文章导航

/